A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who Are Resistant or Refractory to T-DM1
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs DS 8201 (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Breast01
- Sponsors Daiichi Sankyo Company
- 29 Aug 2017 Status changed from not yet recruiting to recruiting as per Daiichi Sankyo media release.
- 10 Aug 2017 Status changed from planning to not yet recruiting.
- 13 Jun 2017 New trial record